PTJ
EVLO

Paul Tudor Jones’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Paul Tudor Jones’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-615
Closed -$60K – 1609
2020
Q2 		$60K Buy
+615
New +$53.8K ﹤0.01% 1103

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Paul Tudor Jones's EVLO Position: Q3 2020 in Review

Paul Tudor Jones sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q3 2020, closing a stake of 615 shares — an estimated $60K sold.

Paul Tudor Jones first reported a position in EVLO in Q2 2020 and held it in 1 quarter. The position peaked at $60K in Q2 2020. 48 funds tracked by Wall St. Rank hold EVLO as of Q3 2020.

  • Paul Tudor Jones reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Paul Tudor Jones sold 615 Evelo Biosciences, Inc. Common Stock shares in Q3 2020, an estimated $60K.
  • Paul Tudor Jones first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Paul Tudor Jones's Evelo Biosciences, Inc. Common Stock position peaked at $60K in Q2 2020.
  • 48 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q3 2020.

Based on Tudor Investment Corp's 13F filing for Q3 2020, filed 16 Nov 2020.